These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

845 related items for PubMed ID: 20380868

  • 1. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 2. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [Abstract] [Full Text] [Related]

  • 3. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT, Levis M, Small D.
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E, Barbarroja N, Torres LA, Buendía P, Velasco F, Dorado G, Torres A, López-Pedrera C.
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [Abstract] [Full Text] [Related]

  • 5. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N, Torres LA, Luque MJ, Carretero RM, Valverde-Estepa A, Lopez-Sanchez LM, Rodriguez-Ariza A, Velasco F, Torres A, López-Pedrera C.
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [Abstract] [Full Text] [Related]

  • 6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 7. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 06; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 10. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
    Scholl S, Müller R, Clement JH, Loncarevic IF, Böhmer FD, Höffken K.
    Leuk Res; 2006 May 06; 30(5):633-42. PubMed ID: 16473406
    [Abstract] [Full Text] [Related]

  • 11. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
    Masson K, Rönnstrand L.
    Cell Signal; 2009 Dec 06; 21(12):1717-26. PubMed ID: 19540337
    [Abstract] [Full Text] [Related]

  • 12. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.
    Acta Pharmacol Sin; 2015 Mar 06; 36(3):385-99. PubMed ID: 25640477
    [Abstract] [Full Text] [Related]

  • 13. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 14. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar 15; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 15. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.
    Cao ZX, Liu JJ, Zheng RL, Yang J, Zhong L, Xu Y, Wang LJ, Zhang CH, Wang BL, Ma S, Wang ZR, Xie HZ, Wei YQ, Yang SY.
    Leukemia; 2012 Aug 15; 26(8):1892-5. PubMed ID: 22402607
    [No Abstract] [Full Text] [Related]

  • 16. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
    Imai N, Shikami M, Miwa H, Suganuma K, Hiramatsu A, Watarai M, Satoh A, Itoh M, Imamura A, Mihara H, Nitta M.
    Br J Haematol; 2006 Dec 15; 135(5):673-82. PubMed ID: 17107349
    [Abstract] [Full Text] [Related]

  • 17. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
    Yigitbasi OG, Younes MN, Doan D, Jasser SA, Schiff BA, Bucana CD, Bekele BN, Fidler IJ, Myers JN.
    Cancer Res; 2004 Nov 01; 64(21):7977-84. PubMed ID: 15520205
    [Abstract] [Full Text] [Related]

  • 18. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
    Giles FJ.
    Leuk Res; 2006 Dec 01; 30(12):1469-70. PubMed ID: 16631251
    [Abstract] [Full Text] [Related]

  • 19. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
    Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI.
    Br J Haematol; 2011 Oct 01; 155(2):198-208. PubMed ID: 21848891
    [Abstract] [Full Text] [Related]

  • 20. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
    Eriksson A, Höglund M, Lindhagen E, Aleskog A, Hassan SB, Ekholm C, Fhölenhag K, Jensen AJ, Löthgren A, Scobie M, Larsson R, Parrow V.
    Biochem Pharmacol; 2010 Nov 15; 80(10):1507-16. PubMed ID: 20705060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.